Additional significant associations were observed with BRAFV600E mutation (18.5% of methylated, compared to 6.4% of unmethylated tumours, p = 0.003) and KRAS mutations (37.0% of methylated tumours, compared to 26.4% of unmethylated tumours, p = 0.049). The gene discussed is KRAS; the disease is neoplasm.